Many scientists who move from research to founding startups often stop using the evidence-based decision-making that defined their scientific careers. This change is driven by several factors, including a focus on technology over market needs, ignoring statistical data, and favoring information that supports their existing beliefs. In addition, most scientist-founders have little formal training in business areas such as commercialization or financial modeling.
According to advisors at Outcome Capital, these issues can delay important breakthroughs from reaching patients because poor business decisions lead to wasted resources and missed opportunities. They note that "missteps in development and commercialization don’t just cost investors; they delay or derail potential breakthroughs from reaching patients."
A common mistake is "technology myopia," where founders become overly attached to their innovations without confirming there is actual demand. Other problems include making decisions without considering relevant data trends ("base rate neglect") and letting personal attachment cloud judgment. As described in the release, "many founders perceive their inventions as extensions of themselves," making it hard for them to accept criticism or revise plans.
One example cited involved a biotech company with a prostate cancer drug candidate. Management expected high returns after a competitor's patent expired but overlooked key facts: the drug was only a slight modification of an existing one and still needed regulatory approval. When market conditions changed and interest waned, the board initially resisted a buyout offer until external advisors presented thorough analysis showing the offer reflected current market realities.
To avoid these pitfalls, experts recommend applying scientific methods to business strategy—starting with testable hypotheses (business plans), gathering objective data through market research, validating assumptions with pilot projects, and seeking feedback from outside experts. The release notes: "Founders should not fear negative or challenging data...transparently acknowledging risks and weaknesses builds credibility with capital providers and partners."
Companies adopting this rigorous approach are more likely to gain trust from investors and partners while avoiding costly errors. As stated in the document: "Companies that build their strategies...upon evidence-driven discipline dramatically improve their chances of sustained growth and successful exits by avoiding costly errors." Ultimately, combining scientific rigor with sound business practices can help bring innovations to patients faster.
